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Abstract
Background: Prion diseases are a family of rare, progressive, neurodegenerative disorders that affect humans and animals.
The most common form of human prion disease, Creutzfeldt-Jakob disease (CJD), occurs worldwide. Variant CJD (vCJD), a
recently emerged human prion disease, is a zoonotic foodborne disorder that occurs almost exclusively in countries with
outbreaks of bovine spongiform encephalopathy. This study describes the occurrence and epidemiology of CJD and vCJD
in the United States.
Methodology/Principal Findings: Analysis of CJD and vCJD deaths using death certificates of US residents for 1979–2006,
and those identified through other surveillance mechanisms during 1996–2008. Since CJD is invariably fatal and illness
duration is usually less than one year, the CJD incidence is estimated as the death rate. During 1979 through 2006, an
estimated 6,917 deaths with CJD as a cause of death were reported in the United States, an annual average of
approximately 247 deaths (range 172–304 deaths). The average annual age-adjusted incidence for CJD was 0.97 per
1,000,000 persons. Most (61.8%) of the CJD deaths occurred among persons $65 years of age for an average annual
incidence of 4.8 per 1,000,000 persons in this population. Most deaths were among whites (94.6%); the age-adjusted
incidence for whites was 2.7 times higher than that for blacks (1.04 and 0.40, respectively). Three patients who died since
2004 were reported with vCJD; epidemiologic evidence indicated that their infection was acquired outside of the United
States.
Conclusion/Significance: Surveillance continues to show an annual CJD incidence rate of about 1 case per 1,000,000
persons and marked differences in CJD rates by age and race in the United States. Ongoing surveillance remains important
for monitoring the stability of the CJD incidence rates, and detecting occurrences of vCJD and possibly other novel prion
diseases in the United States.
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Introduction
Prion diseases, or transmissible spongiform encephalopathies
(TSEs), are a family of rare, progressive, invariably fatal,
neurodegenerative disorders that affect both humans and animals
[1,2]. Prions are agents that are capable of inducing abnormal
folding of the cellular prion protein through a mechanism that
remains a matter of debate.
3 They are the purported unconven-
tional causative agents of this family of diseases that includes
classic Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD) in
humans [1,2,4].
The cause of the most common form of CJD, sporadic CJD, is
unknown, but a widely held hypothesis is that it may result from
spontaneous conversions of the normal prion protein to its
pathogenic form without the necessity of an environmental source
of infection [5–8]. CJD is generally characterized by a rapidly
progressivedementiainolderadultsandusuallydeathoccurswithin
1 year of illness onset [9,10]. In contrast, vCJD occurs almost
exclusively in persons less than 55 years of age. A median illness
duration of 13–14 months from symptom onset until death follows
an incubation period that has been estimated to be about 17 years
[1,2,11]. Clinical and epidemiological differences are important in
distinguishing cases of CJD from vCJD, but neuropathologic study
of brain tissue is required for confirmation [1,2,12]. The distinction
between CJD and vCJD is important, particularly for public health
practitioners, because strong evidence suggests that vCJD, unlike
classic CJD, can be transmitted person-to-person by blood
transfusion and acquired by ingestion of food contaminated with
the agent of bovine spongiform encephalopathy (BSE, commonly
known as ‘‘mad cow’’ disease) [4,13–16].
In the United States, monitoring the occurrence of prion
diseases relies on different surveillance mechanisms, the most
systematic and cost effective of which consists of periodic analyses
of the national multiple cause-of-death data. The present study
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8521describes the epidemiology of CJD and the occurrence of vCJD in
the United States.
Methods
Death records with CJD listed as a cause of death were obtained
from the US national multiple cause-of-death data maintained by
the National Center for Health Statistics (NCHS), Centers for
Disease Control and Prevention (CDC) [17]. Records with the
CJD International Classification of Disease, Ninth Revision (ICD-
9) code of 046.1 for 1979–1998 and the CJD ICD, Tenth Revision
(ICD-10) code of A81.0 for 1999–2006 were selected annually for
analysis [18,19]. The multiple cause-of-death data consist of all
death certificate data, except for 1981 and 1982 data which are
nationally representative weighted samples [20,21].
In addition to using the multiple cause-of-death data to identify
CJD deaths, some CJD records were added and CJD-coded
records removed from the CJD deaths dataset as a result of
information obtained from other surveillance efforts as of June 1,
2009. These efforts, included investigations, in collaboration with
state health authorities, of cases of possible vCJD reported by
clinicians to CDC directly or indirectly through local or state
public health officials or possibly through prion disease surveil-
lance personnel from outside the United States. These efforts also
included routinely collecting and reviewing medical records of
reported cases of suspected or diagnosed cases of CJD in patients
under 55 years of age identified through the multiple cause-of-
death data, or reported to CDC by health department personnel,
members of the CJD Foundation, or staff at the National Prion
Disease Pathology Surveillance Center (NPDPSC). In the present
study, the term CJD or classic CJD refers to the forms of human
prion disease that are not variant CJD unless otherwise specified.
Beginning with the 1999 surveillance year, the CJD death
dataset includes the review of information from computerized
literal text cause-of-death data, the first national application of
such data. These literal text data help to overcome a problem
introduced in 1999 by the new CJD-related ICD-10 coding rule
that would otherwise lead to undercounts of reported CJD deaths.
Creutzfeldt-Jakob disease was considered among a group of
illnesses classified as a ‘‘rare event’’ that required additional
checking for possible errors. However, under the new coding
scheme, coders were instructed to code CJD with a duration of $1
year as ‘‘sequelae of other specified infectious diseases’’ (ICD-10
code B94.8) and not as CJD (A81.0) which prevented identification
of CJD as a reported cause of death [19] (this coding rule has
subsequently been changed beginning in 2007 such that these
deaths will be coded to A81.0). To compensate for this latter
limitation in the surveillance of CJD, deaths beginning in 1999
reported with CJD were identified utilizing a search of the literal
text for CJD and CJD-related terms on death certificate records.
This search used SuperMICAR (Mortality Medical Indexing,
Classification, and Retrieval system), a component of the Mortality
Medical Data System, an automated data system for coding cause
of death [22]. All the information found on the death certificate,
including literal text, is entered into this system. The data are then
processed (e.g., dividing terms, replacing words with synonyms,
dropping unnecessary words, and rearranging words) and
matched to a MICAR dictionary. An input file is generated which
assigns ICD-10 codes to the cause-of-death data. The Super-
MICAR allows for querying and sub-setting of records based on
literal text. It is this functionality that was used to search for CJD-
related terms. In 1999, 18 states had SuperMICAR data available
to NCHS; this number increased to 29 states in 2000, 39 states in
2001, 49 states in 2002, and all states beginning in 2003.
Records identified from the SuperMICAR literal search of CJD-
related terms that did not have an ICD-10 code of A81.0 were
manually reviewed to verify CJD as the probable listed cause of
death. Non-CJD coded death records found to have a CJD-related
literal text through the SuperMICAR process wereadded to the CJD
surveillance database. In addition, records with an ICD-10 code of
A81.0 were matched with the SuperMICAR data and manually
reviewed for possible miscoding as CJD; records were then excluded
if information was found that contradicted a prion disease diagnosis.
The incidence of CJD was estimated by using death rates because
CJD is invariably fatal with over 85% of cases dying within one year
of onset [23,24]. The number of deaths with CJD and the
corresponding US census population estimates for each year were
used to calculate annual and average annual CJD age-specific and
age-adjusted death rates per 1,000,000 persons [25]. Average
annual age-adjusted incidence rates for the overall population and
by sex, race, and geographic region (standard census regions
Northeast, Midwest, South, and West) [26] were calculated by the
direct method using the projected 2000 population for the United
States [27,28]. Risk ratios (RRs) and age-adjusted RRs were
calculated by using Poisson regression analysis with approximate
large-sample 95% confidence intervals (CIs).
Deaths with CJD were also examined for records with diseases
associated with increased exposure to blood or blood products,
specifically hereditary factor VIII (hemophilia A; ICD-9 code
286.0 and ICD-10 code D66), hereditary factor IX (hemophilia B;
codes 286.1 and D67), thalassemia (codes 282.4 and D56), and
sickle cell disease (codes 282.6 and D57) [18,19].
Results
Creutzfeldt-Jakob Disease
From 1979 through 2006,6,917 deaths due to CJD were reported in
the United States (Table 1, Figure 1). CJD was recorded as the
underlying cause for 83% of the deaths. An average of approximately
247 deaths occurred annually, ranging from 172 in 1980 to 304 in
1997. During 2003–2006, the years for which all states submitted literal
text, an average of 288 prion disease deaths were reported annually.
The annual incidence of CJD has remained relatively stable from
1979–2006 in the United States at approximately 1 case per 1,000,000
persons (Figure 1). The incidence was higher among the older
population (Figure 2). The average annual incidence for persons $65
years of age was 4.8 per 1,000,000 persons.
The median age at death for the study period was 68 years (range 21
to 97; Figure 3). The annual median age ranged from 64 to 70 years of
age. Most deaths occurred among persons 60–79 years of age, and the
highest death rates were among those 65–79 years of age (Figure 2,
Figure 3). Fifteen decedents were ,30 years of age. Of these, five were
sporadic cases, four were human growth hormone-associated cases,
three were dura mater-associated cases, and two were familial cases
due to genetic mutation on the prion protein gene; the CJD
classification of one young case from 1981 was unknown. Therefore,
at least 60% of the classified cases ,30 years of age are attributable to
iatrogenic exposure or a geneticmutation.No CJD-related deathswere
reported with hereditary factor VIII (hemophilia A), hereditary factor
IX (hemophilia B), thalassemia, or sickle cell disease.
A majority (52.6%) of the CJD cases occurred in females, but
the average annual age-adjusted incidence for males was higher
than that for females (RR=1.2, 95% CI=1.2–1.3; Table 1).
However, this higher rate for males was only seen among those
$60 years of age and it increased relative to females as age
increased (RR=1.2 for 60–69 year age group and RR=1.4 for
$80 years group; Table 2). The median age at death for males
and females was 67 and 68 years, respectively.
Prion Diseases in the US
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(Table 1). The average annual age-adjusted incidence rate was
more than two and a half times higher for whites than that for
blacks (1.04 and 0.40, respectively; RR=2.7, 95% CI=2.4–3.0).
The average annual age-adjusted incidence rates were highest in
the Northeast region and lowest in the South region. The higher
incidence rate for whites compared to that for blacks were seen in
each of the regions (Table 3).
Variant Creutzfeldt-Jakob Disease
Since 1996, CDC received reports of three subsequently
confirmed cases of vCJD in US residents [30]. The first of these
vCJD case-patients was born in the United Kingdom in late 1979,
moved to Florida in 1992, and experienced onset of vCJD
symptoms in November 2001 at 22 years of age [13]. In January
2002, the patient returned to the United Kingdom for medical
follow-up. The diagnosis of vCJD was initially made based on
clinical symptoms, a characteristic ‘‘pulvinar sign’’ on magnetic
resonance imaging (MRI) of the brain, and the presence of prion
protein in tissue from a tonsil biopsy. The patient died in 2004 in
the United States where neuropathological evaluation of brain
tissue at autopsy provided confirmation of the vCJD diagnosis.
The second US resident with vCJD was also born in the United
Kingdom and lived there throughout the defined period of
increased risk for human exposures to the BSE agent, 1980–1996
[30]. The patient resided in the United States from 2001–2005
Table 1. Creutzfeldt-Jakob disease death rates and deaths, United States, 1979–2006.*
Characteristics Death Rate (95% CI)
{ Risk Ratio (95% CI)
{ Number of Deaths (%)
Age group
,55 years 0.14 (0.13–0.15) reference 781 (11.3)
$55 years
{ 3.97 (3.87–4.07) 29.1 (27.0–31.4) 6136 (88.7)
Sex
Female 0.92 (0.89–0.95) reference 3635 (52.6)
Male
{ 1.05 (1.01–1.09) 1.2 (1.2–1.3) 3282 (47.4)
Race
Black 0.40 (0.35–0.45) reference 254 (3.7)
White
{ 1.04 (1.01–1.07) 2.7 (2.4–3.0) 6541 (94.6)
Other
{ 0.61 (0.50–0.73) 1.5 (1.2–1.9) 121 (1.7)
Region
South 0.84 (0.81–0.88) reference 2103 (30.4)
Northeast
{ 1.08 (1.03–1.13) 1.2 (1.2–1.3) 1656 (24.0)
Midwest
{ 1.04 (0.99–1.09) 1.2 (1.1–1.2) 1793 (25.9)
West
{ 0.98 (0.93–1.04) 1.2 (1.1–1.2) 1363 (19.7)
Total 0.97 (0.95–0.99) 6917
*Deaths obtained from the multiple cause-of-death data for 1979–1998 are based on ICD-9 codes and those beginning in 1999 are based on ICD-10 codes with available
computerized literal death certificate data. Death information was also obtained from other surveillance mechanisms. One death is missing both race and region; and
one death is missing region.
{Death rates expressed per 1,000,000 persons in corresponding group. Death rates and risk ratios are age-adjusted for total, sex, race, and region. The 95% confidence
intervals (CIs) are given.
{p,0.001 for comparison of death rate to that of the referent group.
doi:10.1371/journal.pone.0008521.t001
Table 2. Creutzfeldt-Jakob disease deaths and death rates by age group, sex, race, and region, United States, 1979–2006.*
Age group
(years) Sex Race
{ Region
{
Male Female White Black Other Northeast Midwest South West
Deaths Rate Deaths Rate Deaths Rate Deaths Rate Deaths Rate Deaths Rate Deaths Rate Deaths Rate Deaths Rate
0–49 190 0.1 196 0.1 347 0.1 26 0.04 12 0.05 87 0.1 96 0.1 125 0.1 77 0.1
50–59 530 1.5 600 1.6 1049 1.6 56 0.7 25 0.9 259 1.7 261 1.5 361 1.4 248 1.6
60–69 1224 4.6 1229 4.0 2329 4.6 78 1.5 46 2.7 573 4.7 653 4.8 753 3.7 474 4.3
70–79 1072 6.3 1227 5.2 2200 6.0 75 2.3 24 2.5 574 6.5 609 6.2 672 4.7 444 5.8
$80 266 3.7 383 2.6 616 3.1 19 1.2 14 3.6 163 3.4 174 3.1 192 2.6 120 3.0
*Deaths obtained from the multiple cause-of-death data for 1979–1998 are based on ICD-9 codes, and deaths beginning in 1999 are based on ICD-10 codes with
available computerized literal death certificate data. Death information was also obtained from other surveillance mechanisms. Death rates expressed per 1,000,000.
{One death is missing both race and region; and one death is missing region.
doi:10.1371/journal.pone.0008521.t002
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age. The patient then returned to the United Kingdom where the
diagnosis of vCJD was made based on symptoms and the presence
of the ‘‘pulvinar sign’’ on brain MRI. The patient died in 2006 in
the United Kingdom where vCJD was confirmed by neuropath-
ological testing of brain tissue.
The third US resident with vCJD was born and raised in Saudi
Arabia and beginning in 2001 he occasionally stayed in the United
States for periods of up to 3 months duration [30,31]. The patient
relocated to the United States in 2005 where onset of vCJD
symptoms was experienced in the spring of 2006. The diagnosis of
vCJD was confirmed based on pathological study of adenoid and
Figure 1. Creutzfeldt-Jakob disease deaths and age-adjusted death rates, United States, 1979–2006.
doi:10.1371/journal.pone.0008521.g001
Table 3. Creutzfeldt-Jakob disease deaths and death rates by age group, region and race, United States, 1979–2006.*
Age group
(years) Northeast Midwest South West
White Black White Black White Black White Black
Deaths Rate Deaths Rate Deaths Rate Deaths Rate Deaths Rate Deaths Rate Deaths Rate Deaths Rate
0–49 77 0.1 9 0.1 91 0.1 2 ,0.1 113 0.1 12 0.03 66 0.1 3 0.04
50–59 244 1.8 11 0.7 255 1.6 4 0.3 325 1.5 32 0.8 224 1.7 9 1.3
60–69 551 5.0 15 1.4 636 5.1 12 1.2 705 4.1 43 1.5 437 4.5 8 1.8
70–79 561 6.9 11 1.8 593 6.5 13 2.1 625 5.1 45 2.5 421 6.2 6 2.3
$80 158 3.5 2 0.7 168 3.2 4 1.4 178 2.8 13 1.4 112 3.1 0 0.0
All ages
{ 1591 1.2 48 0.4 1743 1.1 35 0.3 1946 0.9 145 0.4 1260 1.0 26 0.4
*Deaths obtained from the multiple cause-of-death data for 1979–1998 are based on ICD-9 codes, and deaths beginning in 1999 are based on ICD-10 codes with
available computerized literal death certificate data. Death information was also obtained from other surveillance mechanisms. Death rates expressed per 1,000,000.
One death missing is both race and region; and one death is missing region.
{Death rates are age-adjusted.
doi:10.1371/journal.pone.0008521.t003
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2006. The patient had no past history of neurosurgical procedures
or visits to European countries. A previous case of vCJD attributed
to consumption of BSE-contaminated cattle products had been
reported in a Saudi Arabian resident [13].
Discussion
The US incidence of CJD during 1979 through 2006 remained
relatively stable at approximately 1 case per 1,000,000 persons;
this incidence is similar to that reported in many other countries
[23,32–34]. In the present study, the large number of cases
identified in ongoing US surveillance provides insights into the
incidence of CJD by sex. These data demonstrate a majority
(52.6%) of cases in females largely because of the higher number of
women compared to men in the older age populations that
experienced the highest CJD incidence rates. Incidence rates of
CJD by sex were almost the same among persons ,60 years of age
and were higher among males relative to females as the age of the
population groups increased. These findings are consistent with
other studies that indicate a relative excess of cases among females
[33,35–38] but a higher incidence of CJD among the male
population [35,39]. The CJD incidence rates varied regionally,
with the highest rate in the Northeast region and the lowest rates
in the South and West regions. The low rate in the West is of
particular interest due to the longstanding presence of chronic
wasting disease (CWD) among cervids in parts of the region,
particularly in Colorado and Wyoming.
Ongoing US surveillance data continue to demonstrate marked
differences in CJD incidence by race and age. Similar to previous
US reports [23,35,40], the age-adjusted incidence remains more
than 2.5 times higher for whites than for blacks. Although the
reasons for this disparity are unknown, it is possible that genetic
differences and/or under-diagnosis among non-white patients
could contribute. These continuing differences in incidence by
race in the United States raise the possibility that the CJD
incidence in countries where black populations predominate might
be significantly lower than in countries where white populations
predominate, an issue that deserves future study.
The incidence of CJD by age continues to show a pattern that is
strikingly different from that reported for vCJD. Almost all vCJD
cases, including all three US resident cases, died before 55 years of
age. The US surveillance analysis illustrates that only about 11
percent of the CJD cases occurred in this younger US population.
This relatively low proportion, and incidence rate, of CJD cases in
this younger age group occurred despite an increased focus in US
surveillance efforts on suspected cases in this age group since 1996
[12]. Cases of CJD ,30 years of age in the United States remain
Figure 2. Creutzfeldt-Jakob disease age-specific and age-adjusted death rates, United States, 1979–2006.
doi:10.1371/journal.pone.0008521.g002
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iatrogenic exposure or a genetic mutation.
The incidence of CJD dramatically increased with increasing
age until it peaked in the 70–79 year age group. An explanation
for the subsequent drop in incidence of CJD among those 80 years
of age and older, a phenomenon consistently observed in earlier
surveillance studies of CJD [40], remains uncertain. The rarity of
CJD, however, in postmortem studies of possibly clinically
unrecognized cases of CJD in the elderly has led to the suggestion
that the decline in incidence among the elderly is real and unlikely
an artifact of a varying sensitivity, by age group, of surveillance
[41].
Since vCJD was initially recognized in the United Kingdom in
1996, CDC received reports of three subsequently confirmed cases
of vCJD among US residents. The epidemiological data indicated
that each of these cases was most likely infected in the United
Kingdom (2 cases) and in Saudi Arabia (1 case) [13,30].
Through mid-2009, twenty cases of BSE were identified
among cattle in North America, including three that were
identified in the United States [42]. In comparison, the United
Kingdom reported more than 184,000 BSE cases as of
September 30, 2008 and 168 cases of vCJD as of March 2,
2009 [16,43,44]. These BSE/vCJD data suggest that the greatest
risk of vCJD in US residents will continue to be among persons
who as a child or young adult consumed UK beef products
during 1980–1996, the years when such products were most
subject to BSE contamination [12,30]. Such US residents would
include those who were born and raised either in the United
Kingdom or in another country where potentially BSE
contaminated UK beef products were available for consumption.
These persons would also include those who consumed such UK
beef products as a child or young adult during visits abroad. The
United States historically has imported few or no live cattle, beef
products, or livestock nutritional supplements from the United
Kingdom, and throughout the 1990s had banned the import of
live ruminants and most ruminant products from known BSE
countries [16]. Because indigenous BSE cases in North America
were initially documented in 2003 and have continued to occur
through 2008, albeit in relatively low numbers [42], the results of
ongoing US vCJD surveillance receives considerable attention,
particularly among those concerned about the emergence of
indigenous vCJD cases in the United States.
Limitations of using the US national multiple cause-of-death
data include possible coding and reporting discrepancies, and
misdiagnosis of CJD as a cause of death. However, the use of
national death certificate data has been found to be a reasonably
sensitive ($80%) method compared to more active methods of
CJD case ascertainment [45,46]. Furthermore, the US prion
disease surveillance includes activities carried out by the NPDPSC.
The NPDPSC, established by CDC in collaboration with the
Figure 3. Creutzfeldt-Jakob disease deaths and death rates by age group, United States, 1979–2006.
doi:10.1371/journal.pone.0008521.g003
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testing available free-of-charge to US physicians that can help to
improve the accuracy of prion disease diagnoses [2,47]. This
center can confirm or refute the presence of vCJD, and also detect
other unusual or new prion diseases [48]. The prion surveillance
efforts further utilizes the laboratory test results in the investigation
and identification of CJD among persons ,55 years of age.
Finally, the use of the SuperMICAR procedure beginning in 1999
(fully in 2003) enables detection of deaths with prion disease even if
cause of death on the death certificate is miscoded (e.g., an
inappropriate coding rule, a misinterpretation or a misreading of
the certificate) [22].
The occurrence of CJD and vCJD continues to be an
international and national concern. Ongoing CJD and vCJD
surveillance in many countries of the world, including the United
States, remains critical for determining the extent to which the
agents of classic and possibly atypical BSE may cause disease in
humans [49]. Physicians and health care workers in the United
States are encouraged to indicate CJD, as appropriate, on death
certificates for all their patients who die with CJD or vCJD. In
addition, health care workers who provide care to patients with
suspected or clinically diagnosed CJD or vCJD should discuss
possible options for autopsy with their local and state health
department and the NPDPSC. Brain tissue specimens obtained by
autopsy from these patients may be submitted to the NPDPSC for
further analysis and confirmation of the CJD diagnosis. The
ongoing prion disease surveillance and diagnostic testing is
important for monitoring the stability of the CJD incidence rates,
and detecting possible occurrences of vCJD and other new prion
diseases in the United States.
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